Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Antitumor immune response and chemotherapy-induced immunomodulation in colon cancer patients represented the rationale to design new strategies, like GOLFIG chemoimmunotherapy (gemcitabine, oxaliplatin, 5-fluorouracil/folinic acid, granulocyte macrophage colony-stimulating factor, and aldesleukine), that resulted a safe and very active regimen. Antitumor activity and immunity feedback to GOLFIG were strictly correlated with the best outcome observed in patients with autoimmunity signs, increase of central memory T cells, and decrease of regulatory T cells (Treg) in the peripheral blood. We thus investigated a potential correlation between the Treg tumor infiltration at diagnosis and the clinical outcome in a current randomized phase 3 trial aimed to compare the GOLFIG regimen with the standard FOLFOX chemotherapy (GOLFIG-2). An immunohistochemistry study was carried out to quantify the infiltration of Treg/FoxP3+ T lymphocytes in tumor samples of 57 patients enrolled in the GOLFIG-2 trial. Treg tumor infiltration scores were correlated with overall survival, treatment-relative survival, and progression-free survival (PFS). Higher Treg tumor infiltration scores were associated with a better prognosis in the whole series (Treg high score vs. low score: overall survival=mean 43.2 mo vs. 28.6 mo, P=0.0005) and a better outcome after treatment (Treg high score vs. low score: PFS=mean 15.8 mo vs. 8.8 mo, P=0.0009; treatment-relative survival=mean 23.1 mo vs. 18.2 mo, P=0.004). PFS was significantly longer in GOLFIG high versus all other subgroups (mean 18.1 mo vs. 9.9 mo, P=0.01). Our results suggest that a higher FoxP3+ T-lymphocyte tumor infiltration score is a favorable prognostic factor in colon cancer patients undergoing chemo or chemoimmunotherapy.
Correale
Pierpaolo
P
Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy.
Rotundo
Maria Saveria
MS
Del Vecchio
Maria Teresa
MT
Remondo
Cinzia
C
Migali
Cristina
C
Ginanneschi
Chiara
C
Tsang
Kwong Y
KY
Licchetta
Antonella
A
Mannucci
Susanna
S
Loiacono
Lucia
L
Tassone
Pierfrancesco
P
Francini
Guido
G
Tagliaferri
Pierosandro
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000175:diagnosis* / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D003110:Colonic Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D051858:Forkhead Transcription Factors / Q000096:biosynthesis; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy; D002955:Leucovorin / Q000627:therapeutic use; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D000077150:Oxaliplatin; D011379:Prognosis; D011994:Recombinant Proteins; D016019:Survival Analysis; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D000093542:Gemcitabine
C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D009944:Organoplatinum Compounds; D011994:Recombinant Proteins; D000077150:Oxaliplatin; D003841:Deoxycytidine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D002955:Leucovorin; D005472:Fluorouracil; D000093542:Gemcitabine
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6
15980149
Blood. 2006 Aug 1;108(3):804-11
16861339
J Clin Oncol. 2007 Jun 20;25(18):2586-93
17577038
J Clin Oncol. 2005 Sep 1;23(25):6043-53
16087944
Nat Med. 2004 Sep;10(9):942-9
15322536
J Immunol. 2005 Aug 1;175(3):1456-63
16034082
Blood. 2008 Dec 15;112(13):4953-60
18820132
Curr Top Microbiol Immunol. 2005;293:287-302
15981485
Br J Cancer. 2004 May 4;90(9):1710-4
15150625
Eur J Immunol. 2005 Jun;35(6):1681-91
15902688
Eur J Immunol. 2004 Feb;34(2):336-44
14768038
Oncol Rep. 2007 Nov;18(5):1115-22
17914561
N Engl J Med. 2006 Feb 16;354(7):709-18
16481638
Eur J Cancer. 2001 May;37(7):892-902
11313178
J Clin Oncol. 2000 Aug;18(16):2938-47
10944126
Semin Cancer Biol. 2006 Apr;16(2):124-36
16443370
J Immunother. 2008 Feb-Mar;31(2):132-47
18481383
J Clin Oncol. 2009 Jan 10;27(2):186-92
19064967
Gastroenterology. 2009 Oct;137(4):1270-9
19577568
J Clin Oncol. 2006 Dec 1;24(34):5373-80
17135638
Anim Health Res Rev. 2004 Dec;5(2):227-34
15984329
Evid Based Complement Alternat Med. 2006 Mar;3(1):25-30
16550220
J Clin Oncol. 2009 Apr 10;27(11):1746-52
19255331
Clin Cancer Res. 2008 Jul 1;14(13):4192-9
18593999
Ann N Y Acad Sci. 2005 Dec;1062:127-36
16461795
Blood. 2005 Apr 1;105(7):2862-8
15591121
N Engl J Med. 2005 Feb 3;352(5):476-87
15689586
Eur J Dermatol. 2003 Mar-Apr;13(2):111-6
12695124
J Clin Oncol. 2005 Dec 10;23(35):8950-8
16061910
J Exp Med. 2006 Mar 20;203(3):489-92
16533888
J Clin Invest. 2008 Jun;118(6):1991-2001
18523649